Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA-Reference-Cited by-同舟云学术

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA

Published:2023-03 Issue: Volume:Volume 19 Page:693-707
ISSN:1178-2021
Container-title:Neuropsychiatric Disease and Treatment
language:en
Short-container-title:NDT

Author:

Chen Xu,Hou Xuan,Bai Daisy^ORCID,Lane Rosanne,Zhang Chong,Canuso Carla,Wang Gang,Fu Dong-Jing^ORCID

Publisher

Informa UK Limited

Reference35 articles.

1. Morbidity in Depressive Disorders

2. World Health Organization Depression Fact Sheet; 2021. Available from: http://www.who.int/en/news-room/fact-sheets/detail/depression. Accessed July 11, 2022.

3. Prevalence of mental disorders in China: a cross-sectional epidemiological study

4. Treatment-resistant depression: therapeutic trends, challenges, and future directions

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intravenous patient-controlled analgesia with esketamine improves early depressive symptoms in patients with postherpetic neuralgia: a single-center retrospective cohort study;BMC Psychiatry;2024-08-27

2. Glutamatergic Modulators for Major Depression from Theory to Clinical Use;CNS Drugs;2024-08-16

3. New and emerging treatments for major depressive disorder;BMJ;2024-07-08

4. Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis;Journal of Affective Disorders;2024-07

5. Balancing Evidence and Need: Variation in US Commercial Payer Coverage of Esketamine;Clinical Therapeutics;2024-07